KindredBio Revenue and Competitors

Location

$62.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • KindredBio's estimated annual revenue is currently $19.7M per year.(i)
  • KindredBio received $46.0M in venture funding in January 2019.
  • KindredBio's estimated revenue per employee is $155,000
  • KindredBio's total funding is $62.1M.

Employee Data

  • KindredBio has 127 Employees.(i)
  • KindredBio grew their employee count by -18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Our goal is to save lives and relieve suffering for the animals in our lives. We bring a determination and dedication to unite our expertise and research creativity in developing humane, effective, and safe therapies for our animal companions that people enjoy today. We are veterinary therapeutics, redefined. As one of the first pet biotech companies in the world, we understood early that to quickly deliver veterinary therapeutics in unmet and under served areas we needed a revolutionary approach. By leveraging the similarities between human and pet diseases, we are creating cutting edge versions of successful human drugs and biologics. Our belief is that this can substantially increase success rate and reduce time to market - increasing the quality of life for the pets with whom we share so much of our lives, providing the veterinary community with innovative treatment options, and, we anticipate, generating solid returns for our investors.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$62.1M

Total Funding

127

Number of Employees

$19.7M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KindredBio News

2021-06-16 - Elanco Announces Agreement to Acquire Kindred Biosciences

GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio,NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical com ...

2021-06-02 - Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint wa ...

2021-05-11 - KINDRED BIOSCIENCES, INC. Kindred Biosciences : Announces First Quarter 2021 Financial Results

SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first qua ...

2019-09-12 - Kindred Biosciences Awarded a Contract by the National ...

As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analytical services to meet the needs of the ...

2019-08-31 - Kindred Biosciences to Participate in HC Wainwright Global ...

During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, study ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.8M12749%$27.2M
#2
$15M127-2%N/A
#3
$29.3M133-20%N/A
#4
$30.6M1357%$26M
#5
$34.3M13747%N/A

KindredBio Funding

DateAmountRoundLead InvestorsReference
2014-03-19$UndisclosedUndisclosedLeerink Partners LLCArticle
2014-04-04$54.0MUndisclosedLeerink Partners LLCArticle
2014-04-09$58.1MUndisclosedLeerink Partners LLCArticle
2017-07-13$25.8MUndisclosedLadenburg Thalmann & Co. IncArticle
2018-06-26$57.2MUndisclosedCantor Fitzgerald & CoArticle
2019-01-21$46.0MUndisclosedBarclays Capital IncArticle